Browsing by Author "Bragazzi, Nicola Luigi"
Now showing items 1-5 of 5
-
The COVID-19 pandemic – How many times were we warned before?
Mahroum, Naim; Seida, İsa; Esirgün, Şevval Nil; Bragazzi, Nicola Luigi (Elsevier B.V., 2022)Infectious diseases are known to act in both predictable and unpredictable ways, which leads to the notions of emerging and reemerging infectious diseases. Emerging diseases with their disastrous consequences might be ... -
COVID-19 vaccination and the rate of immune and autoimmune adverse events following immunization: Insights from a narrative literature review
Mahroum, Naim; Lavine, Noy; Ohayon, Aviran; Seida, Ravend; Alwani, Abdulkarim; Alrais, Mahmoud; Zoubi, Magdi; Bragazzi, Nicola Luigi (Frontiers Media S.A., 2022)Despite their proven efficacy and huge contribution to the health of humankind, vaccines continue to be a source of concern for some individuals around the world. Vaccinations against COVID-19 increased the number of ... -
HIV pre-exposure prophylaxis and its impact on the gut microbiome in men having sex with men
Bragazzi, Nicola Luigi; Khamisy-Farah, Rola; Tsigalou, Christina; Mahroum, Naim (Frontiers Media S.A., 2022)HIV/AIDS still imposes a high epidemiological and societal burden. Together with antiretroviral therapy, pre-exposure prophylaxis (PrEP) represents a fundamental tool in the fight against HIV/AIDS. PrEP is considered ... -
Infectious side effects of baricitinib: A big data analysis based on VigiBase
Mahroum, Naim; Özkan, Mehmet Fatih; Abalı, Tunahan; Yılmaz, Mesut; Bragazzi, Nicola Luigi (Elsevier B.V., 2023)Dear Editor, Baricitinib (known as “Olumiant”), is an inhibitor of Janus- associated kinase 1 and 2 (JAK1 and JAK2) initially introduced for the treatment of rheumatoid arthritis (RA), and later for systemic lupus erythematosus ... -
Systematic review and meta-analysis of tocilizumab therapy versus standard of care in over 15,000 COVID-19 pneumonia patients during the first eight months of the pandemic
Mahroum, Naim; Watad, Abdulla; Bridgewood, Charlie; Mansour, Muhammad; Nasr, Ahmad; Hussein, Amr; Khamisy-Farah, Rola; Farah, Raymond; Gendelman, Omer; Lidar, Merav; Shoenfeld, Yehuda; Amital, Howard; Kong, Jude Dzevela; Wu, Jianhong; Bragazzi, Nicola Luigi; McGonagle, Dennis (MDPI, 2021)Background. Tocilizumab is an anti-IL-6 therapy widely adopted in the management of the so-called "cytokine storm" related to SARS-CoV-2 virus infection, but its effectiveness, use in relation to concomitant corticosteroid ...
